eculizumab sold brand name soliris among others recombinant humanized monoclonal antibody used treat paroxysmal nocturnal hemoglobinuria pnh atypical hemolytic uremic syndrome ahus generalized myasthenia gravis neuromyelitis people pnh reduces destruction red blood cells need blood transfusion appear affect risk eculizumab first drug approved uses approval granted based small given intravenous side effects include risk meningococcal infections prescribed enrolled follow risk evaluation mitigation strategy involves counseling people ensuring humanized monoclonal antibody functioning terminal complement developed manufactured marketed alexion eculizumab used treat atypical hemolytic uremic syndrome ahus paroxysmal nocturnal hemoglobinuria people pnh improves quality life decreases need blood transfusions appear affect risk appear change risk blood clots myelodysplastic syndrome acute myelogenous leukemia aplastic eculizumab also used treat neuromyelitis optica spectrum disorder adults antibody eculizumab also explored treatment deficiency also known chaple syndrome rare genetic disorder immune system approval compassionate offlabel use kurolap colleagues treated patients drug found positive clinical laboratory outcomes eculizumab carries black box warning risk meningococcal infections prescribed doctors enrolled follow risk evaluation mitigation strategy required fda involves doctors counseling people prescribing drug giving educational materials ensuring vaccinated must eculizumab inhibits terminal complement activation therefore makes people vulnerable infection encapsulated organisms lifethreatening fatal meningococcal infections occurred people received people receiving eculizumab times greater risk developing invasive meningococcal due increased risk meningococcal infections meningococcal vaccination recommended least weeks prior receiving eculizumab unless risks delaying eculizumab therapy outweigh risk developing meningococcal infection case meningococcal vaccine administered soon serogroup c w conjugate meningococcal vaccine serogroup b meningococcal vaccine recommended people receiving receiving recommended vaccinations may prevent meningococcal infections especially nongroupable n became clear eculizumab caused invasive meningococcal disease despite vaccination interferes ability antimeningococcal antibodies protect invasive drugs labels also carry warnings severe anemia arising destruction red blood cells well severe cases blood clots forming small blood headaches common adverse effects occurring people take common adverse effects occurring people take drug include infections pneumonia upper respiratory tract infection colds urinary tract infection loss white blood cells loss red blood cells anaphylactic reaction hypersensitivity reaction loss appetite mood changes like depression anxiety sense tingling numbness blurred vision vertigo ringing ears heart palpitations high blood pressure low blood pressure vascular damage peritonitis constipation upset stomach swollen belly itchy skin increased sweating blotches small bleeds skin skin redness hives muscle spasms bone pain back pain neck pain swollen joints kidney damage painful urination spontaneous erections general edema chest pain weakness pain infusion site elevated eculizumab specifically binds terminal complement component acts late stage complement activated involved activating host cells thereby attracting proinflammatory immune cells also destroying cells triggering pore formation inhibiting complement cascade point normal diseasepreventing functions proximal complement system largely preserved properties promote inflammation cell destruction eculizumab inhibits cleavage convertase potent anaphylatoxin prothrombotic proinflammatory properties forms terminal complement complex also prothrombotic proinflammatory effects cause complementmediated events characteristic pnh metabolism eculizumab thought occur via lysosomal enzymes cleave antibody generate small peptides amino acids volume distribution eculizumab humans approximates eculizumab recombinant humanized monoclonal antibody complement protein immunoglobulin gkappa iggÎº consisting human constant regions murine complementaritydetermining regions grafted onto human framework light heavy chain variable regions compound contains two acid heavy chains two acid light chains molecular weight approximately kilodaltons eculizumab approved us food drug administration fda march treatment eculizumab exclusivity rights protects competition fda approved september treatment ahus designated orphan fda approval based two small prospective trials people european medicines agency approved treatment pnh june november treatment health canada approved treat pnh drug treat eculizumab approved fda nmo based results prevent study showed eculizumab may provide substantive benefits patients pnh terms life expectancy quality life high incremental alexion priced soliris expensive drug approximately year united states per year ongoing treatment year canada soliris generated billion april may controversy arose belgium media revealed government refused pay sevenyearold boys treatment soliris expensive boys medicine cost every two public relations agency working alexion reportedly looking story helped boys parents communicate story press order pressure governments reimburse cost several politicians stated company attempting blackmail government charges alexion may agreement reached government reimburse cost medicine beginning july december new zealands government pharmaceutical buyer pharmac declined proposal subsidize drug alexion refused budge per person per year price pharmacs economic analysis determined price would need halved drug costeffective enough pharmacs decision upset many people pnh new zealand although pharmac ruled reviewing decision later date drug made available lower december provincial government ontario canada negotiated price manufacturer drug approved health canada treat ahus people apply compassionate grounds casebycase basis example individuals urgently hospitalized due immediate life limb organthreatening complication already funded ontario government treatment another rare illness paroxysmal nocturnal hemoglobinuria pnh bulkbuy deal reached provincial premiers february canadas drugprice regulator took rare step calling hearing soliris accusing alexion exceeding permissible price cap highest international price comparison june patented medicine prices review board pmprb canadian patent act held preliminary hearing ottawa ontario examine allegations john haslam president general manager vaughan ontariobased alexion canada named one alexion charges canada per person per year anywhere else alexion denies claim canada provincial drug plans already negotiated secret discounts soliris many patients eculizumab pnh associated additional life years quality life years qalys high incremental cost million substantial opportunity cost canadian study calculated cost per lifeyeargained treatment million cost per qualityadjustedlifeyear million incremental cost per life year per qaly gained million million respectively based established thresholds opportunity cost funding eculizumab discounted qalys per patient industry analysts academic researchers agreed high price orphan drugs eculizumab related research development manufacturing costs price arbitrary become profitable traditional brazilian universal health care system annually provided citizens initially patients got access suing government demanding right treatment medication gave biggest cost system judicial way accounting million reais us million time treat second counting system regular medications biggest cost brazils supreme court ruled april break patent soliris brazil enabling produced december incorporated public health care biosimilar developed amgen prevented entering us market biosimilar version branded elizaria available february committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending granting marketing authorization medicinal product bekemv intended treatment adults children paroxysmal nocturnal applicant medicinal product amgen technology ireland unlimited bekemv biosimilar medicinal highly similar reference product soliris eculizumab authorized eu june data show bekemv comparable quality safety efficacy bekemv approved medical use european union april epysqli approved medical use european union may immune activation dostarlimab ibalizumab httpsenwikipediaorgwikieculizumab